Oppenheimer Sets $145 Target for Dianthus Therapeutics, Sees 79% Upside

Key Facts

1Oppenheimer analyst Trevor Allred set a $145 price target for DNTH, suggesting a potential upside of 79.28%.

2The stock has seen a 13-fold increase over the past two years, driven by advancements in autoimmune disease treatments.

3The stock surged 23.74% to $80.68, hitting a one-year high of $84.86 during intraday trading.

Oppenheimer analyst Trevor Allred has issued a highly bullish outlook for Dianthus Therapeutics (DNTH), setting a new price target of $145. This target implies a potential upside of approximately 79.28% from current levels, reflecting strong confidence in the company's clinical pipeline. The stock responded positively to the news, surging 23.74% to reach $80.68 and hitting a new one-year high of $84.86 during intraday trading. Dianthus has demonstrated remarkable momentum, with its share price increasing 13-fold over the past two years due to advancements in autoimmune disease treatments. The upgrade is primarily driven by progress in therapies for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and other inflammatory conditions. Market experts believe this sustained clinical progress will continue to drive value for the NASDAQ-listed biotech firm.